Krishnan Rajesh 4

Accession 0001209191-23-052014

CIK 0001260990other

View on SEC.gov Company Profile

Filed

Oct 3, 8:00 PM ET

Accepted

Oct 4, 4:59 PM ET

Size

35.8 KB

Accession

0001209191-23-052014

Insider Transaction Report

Form 4

Period: 2023-10-02

Oncternal Therapeutics, Inc.ONCT

Krishnan Rajesh

Chief Technology Officer

Transactions

Award
Stock Option
2023-10-02+75,000→ 75,000 total
Exercise: $0.31Exp: 2029-08-12→ Common Stock (75,000 underlying)
Award
Stock Option
2023-10-02+40,000→ 40,000 total
Exercise: $0.31Exp: 2029-09-12→ Common Stock (40,000 underlying)
Award
Stock Option
2023-10-02+160,000→ 160,000 total
Exercise: $0.31Exp: 2031-01-06→ Common Stock (160,000 underlying)
Disposition to Issuer
Stock Option
2023-10-02−75,000→ 0 total
Exercise: $4.30Exp: 2029-08-12→ Common Stock (75,000 underlying)
Disposition to Issuer
Stock Option
2023-10-02−40,000→ 0 total
Exercise: $5.76Exp: 2029-09-12→ Common Stock (40,000 underlying)
Disposition to Issuer
Stock Option
2023-10-02−12,470→ 0 total
Exercise: $3.33Exp: 2030-03-17→ Common Stock (12,470 underlying)
Disposition to Issuer
Stock Option
2023-10-02−160,000→ 0 total
Exercise: $4.59Exp: 2031-01-06→ Common Stock (160,000 underlying)
Disposition to Issuer
Stock Option
2023-10-02−220,000→ 0 total
Exercise: $0.96Exp: 2033-02-21→ Common Stock (220,000 underlying)
Award
Stock Option
2023-10-02+12,470→ 12,470 total
Exercise: $0.31Exp: 2030-03-17→ Common Stock (12,470 underlying)
Award
Stock Option
2023-10-02+177,050→ 177,050 total
Exercise: $0.31Exp: 2032-01-20→ Common Stock (177,050 underlying)
Award
Stock Option
2023-10-02+28,750→ 28,750 total
Exercise: $0.31Exp: 2032-07-28→ Common Stock (28,750 underlying)
Award
Stock Option
2023-10-02+220,000→ 220,000 total
Exercise: $0.31Exp: 2033-02-21→ Common Stock (220,000 underlying)
Disposition to Issuer
Stock Option
2023-10-02−177,050→ 0 total
Exercise: $1.94Exp: 2032-01-20→ Common Stock (177,050 underlying)
Disposition to Issuer
Stock Option
2023-10-02−28,750→ 0 total
Exercise: $1.04Exp: 2032-07-28→ Common Stock (28,750 underlying)

Footnotes (8)

[F1]The shares subject to the option (the "Option Shares") are fully vested.
[F2]On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged.
[F3]25% of the Option Shares vested on January 6, 2022, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service.
[F4]25% of the Option Shares vested on January 20, 2023, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service.
[F5]50% of the Option Shares vested on July 3, 2023, and 50% of the Option Shares vest on January 3, 2024, subject to the recipient's continued service. All of the Option Shares vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan).
[F6]25% of the Option Shares vest on February 21, 2024, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service.
[F7]The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to October 2, 2024: (i) recipient's employment or service terminates, other than due to death, disability, or circumstances giving rise to severance under the recipient's employment agreement (a "Qualifying Termination"); or (ii) the option is exercised.
[F8]The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to April 2, 2025: (i) recipient's employment or service terminates, other than due to a Qualifying Termination; or (ii) the option is exercised.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

Oncternal Therapeutics, Inc.

CIK 0001260990

→

Entity typeother

Related Parties

filerCIK 0001864793

Filing Metadata

Form type: 4
Filed: Oct 3, 8:00 PM ET
Accepted: Oct 4, 4:59 PM ET
Size: 35.8 KB

View on SEC.gov